ATE229004T1 - Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung - Google Patents
Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellungInfo
- Publication number
- ATE229004T1 ATE229004T1 AT98400731T AT98400731T ATE229004T1 AT E229004 T1 ATE229004 T1 AT E229004T1 AT 98400731 T AT98400731 T AT 98400731T AT 98400731 T AT98400731 T AT 98400731T AT E229004 T1 ATE229004 T1 AT E229004T1
- Authority
- AT
- Austria
- Prior art keywords
- nmda receptor
- useful
- disease
- prevention
- sulfide derivatives
- Prior art date
Links
- AREWYRAETFMKAH-UHFFFAOYSA-N 1-sulfidoquinolin-1-ium Chemical class C1=CC=C2[N+]([S-])=CC=CC2=C1 AREWYRAETFMKAH-UHFFFAOYSA-N 0.000 title 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 208000010496 Heart Arrest Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 241001279009 Strychnos toxifera Species 0.000 abstract 1
- -1 analgesic Substances 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000002932 anti-schizophrenic effect Effects 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229960005453 strychnine Drugs 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019970011958A KR19980075708A (ko) | 1997-03-31 | 1997-03-31 | Nmda 수용체 길항제로 작용하는 3-아릴티오-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법 |
| KR1019970013818A KR100236466B1 (ko) | 1997-04-15 | 1997-04-15 | Nmda 수용체 길항제로 작용하는 3-헤테로사이클릭 메르캅토-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법 |
| KR1019970058546A KR100301129B1 (ko) | 1997-11-06 | 1997-11-06 | 3-(치환-페닐티오)-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE229004T1 true ATE229004T1 (de) | 2002-12-15 |
Family
ID=27349502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98400731T ATE229004T1 (de) | 1997-03-31 | 1998-03-27 | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5990126A (de) |
| EP (1) | EP0869122B1 (de) |
| JP (1) | JP3130502B2 (de) |
| AT (1) | ATE229004T1 (de) |
| DE (1) | DE69809827D1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4253126B2 (ja) * | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ調節剤 |
| US6583157B2 (en) * | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| JP3772019B2 (ja) | 1998-04-21 | 2006-05-10 | 株式会社東芝 | 蒸気タービン |
| JP3774321B2 (ja) | 1998-04-24 | 2006-05-10 | 株式会社東芝 | 蒸気タービン |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| JP2000291403A (ja) | 1999-04-02 | 2000-10-17 | Toshiba Corp | 蒸気タービン |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| GB9917822D0 (en) * | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| JP4592130B2 (ja) * | 1999-08-05 | 2010-12-01 | 大塚化学株式会社 | チオ酢酸アミド化合物及び農園芸用殺菌剤 |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| WO2001092925A1 (fr) * | 2000-05-31 | 2001-12-06 | Mitsui Chemicals, Inc. | Materiau optique et element optique contenant un compose de sulfure aromatique et compose de sulfure aromatique |
| US20030171399A1 (en) * | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| EP1436258A4 (de) * | 2001-03-08 | 2005-03-23 | Univ Emory | Ph-wert-abhängige nmda-rezeptorantagonisten |
| WO2003010540A1 (en) * | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| WO2005086904A2 (en) * | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| US8916550B2 (en) * | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| EP2392328A1 (de) * | 2005-05-09 | 2011-12-07 | Hydra Biosciences, Inc. | Verbindungen zur Modulierung der TRPV3-Funktion |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| US8420680B2 (en) | 2007-06-29 | 2013-04-16 | Emory University | NMDA receptor antagonists for neuroprotection |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| US8815508B2 (en) | 2008-08-12 | 2014-08-26 | Zinfandel Pharmaceuticals, Inc. | Method of identifying disease risk factors |
| BRPI0923476A2 (pt) | 2008-12-24 | 2016-01-19 | Astrazeneca Ab | composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica |
| EP3106165B1 (de) | 2011-01-10 | 2019-02-27 | Zinfandel Pharmaceuticals, Inc. | Verfahren und arzneimittelprodukte zur behandlung von morbus alzheimer |
| KR101197618B1 (ko) | 2012-03-13 | 2012-11-07 | 한국화학연구원 | 결핵의 예방 또는 치료용 약제학적 조성물 |
| EP4574822A2 (de) | 2020-01-29 | 2025-06-25 | Kamari Pharma Ltd. | Verbindungen und zusammensetzungen zur verwendung beim behandeln von hauterkrankungen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127574A (en) * | 1976-03-01 | 1978-11-28 | Sandoz, Inc. | 4-Hydroxy-3-sulfonyl-quinolin-2(1H)-ones |
| US4121587A (en) * | 1977-03-03 | 1978-10-24 | National Patent Development Corporation | Root canal delivery syringe |
| EP0459561B1 (de) * | 1990-05-31 | 1995-09-20 | MERCK SHARP & DOHME LTD. | Dioxo-tetrahydrochinolinderivate |
| GB9022785D0 (en) * | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
| GB9026389D0 (en) * | 1990-12-05 | 1991-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| US5622965A (en) * | 1993-03-12 | 1997-04-22 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists |
| EP0685466A1 (de) * | 1994-06-02 | 1995-12-06 | Ciba-Geigy Ag | 3-Heteroaliphatyl- und 3-Hetero-(aryl)aliphatyl-2(1H)-chinolonderivate |
-
1998
- 1998-03-27 DE DE69809827T patent/DE69809827D1/de not_active Expired - Lifetime
- 1998-03-27 AT AT98400731T patent/ATE229004T1/de not_active IP Right Cessation
- 1998-03-27 EP EP98400731A patent/EP0869122B1/de not_active Expired - Lifetime
- 1998-03-30 JP JP10084760A patent/JP3130502B2/ja not_active Expired - Fee Related
- 1998-03-31 US US09/052,752 patent/US5990126A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10310575A (ja) | 1998-11-24 |
| EP0869122A1 (de) | 1998-10-07 |
| DE69809827D1 (de) | 2003-01-16 |
| JP3130502B2 (ja) | 2001-01-31 |
| EP0869122B1 (de) | 2002-12-04 |
| US5990126A (en) | 1999-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE229004T1 (de) | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung | |
| CY1107401T1 (el) | Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson | |
| EP0915094A4 (de) | Morphinanderivate und ihre medizinische Anwendung | |
| CY1108674T1 (el) | Κυκλικα αμιδια | |
| DE69628051D1 (de) | Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung | |
| WO1993011115A3 (en) | Quinolone derivatives and their use as nmda and ampa receptor antagonists | |
| NO20071967L (no) | Imidazo-benzodiazepinderivater | |
| ATE213738T1 (de) | Azaheterocyclische tachykinin rezeptor antagoniste; nk1 und nk2 | |
| ES2195943T3 (es) | Compuestos heteroaromaticos biciclicos y triciclicos. | |
| GEP20104959B (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
| ATE289310T1 (de) | Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren | |
| ES2092639T3 (es) | Mejoras en o relativas a antagonistas de receptores de aminoacidos excitatorios. | |
| ATE466858T1 (de) | 3-arylisoxazol-4-carbonylbenzofuranderivative | |
| MXPA04006184A (es) | Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c. | |
| EP1505063A4 (de) | Benzimidazolderivate | |
| AP2002002664A0 (en) | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. | |
| ES2138181T3 (es) | Heterociclos biciclicos como antagonistas de la neurokinina. | |
| RS20050892A (en) | Imidazole derivatives as glutamate receptor antagonists | |
| ATE301642T1 (de) | Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten | |
| CA2601098A1 (en) | Dipyrazoles as central nervous system agents | |
| WO2003057213A3 (en) | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor | |
| NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
| DE502004007387D1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
| BR9712577A (pt) | Derivado de benzoxazola | |
| Takano et al. | Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |